Neuronetics Reports Preliminary Fourth Quarter and Fiscal Year 2022 Financial Results
January 09, 2023 08:30 ET
|
Neuronetics
MALVERN, Pa., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics Announces Appointment of Joseph H. Capper to its Board of Directors
December 29, 2022 16:29 ET
|
Neuronetics
MALVERN, Pa., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever...
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 07, 2022 16:30 ET
|
Neuronetics
MALVERN, Pa., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics Announced as a Winner by 2022 Merit Awards for HealthCare in the Patient Care Category
December 05, 2022 08:32 ET
|
Neuronetics
MALVERN, Pa., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics to Present at the Piper Sandler 34th Annual Healthcare Conference
November 21, 2022 16:30 ET
|
Neuronetics
MALVERN, Pa., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics Announces NeuroStar® Advanced Therapy for Mental Health System Innovations
November 14, 2022 08:33 ET
|
Neuronetics
MALVERN, Pa., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 09, 2022 20:04 ET
|
Neuronetics
MALVERN, Pa., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics Reports Third Quarter 2022 Financial and Operating Results
November 08, 2022 07:30 ET
|
Neuronetics
MALVERN, Pa., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever...
Neuronetics Announced as Winner by 2022 Merit Awards for Technology
October 31, 2022 08:31 ET
|
Neuronetics
MALVERN, Pa., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics Announces Updated TMS Coverage Policies That Will Expand Patient Access to NeuroStar TMS Therapy for Mental Health
October 25, 2022 10:31 ET
|
Neuronetics
MALVERN, Pa., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...